Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084253 · ClinicalTrials.gov registry record · Phase 4
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
A Phase 4 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00084253 is a Phase 4 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00084253, a Phase 4 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV) works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine to slow or stop the progression of HIV infection in patients who have never used anti-HIV drugs.
Conditions Studied
Interventions
- DRUG Atazanavir/ Stavidine / Lamivudine
- DRUG Atazanavir-Ritonavir/ Stavidine / Lamivudine
Study Locations (1)
New Jersey
- Various locations within the US - Call For Information
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084253
The ClinicalTrials.gov registry entry for NCT00084253 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Atazanavir/ Stavidine / Lamivudine is the first listed.
NCT00084253 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00084253 about?
NCT00084253 is a clinical study titled "Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients". The purpose of this study is to find out if 300 mg of ATV plus 100 mg of ritonavir (RTV) works as well as 400 mg of ATV alone as part of a regimen with stavudine XR and lamivudine to slow or stop the progression of HIV infection in patients who have never used anti-HIV drugs.
What is the current status of trial NCT00084253?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2004-06.
What conditions does trial NCT00084253 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00084253?
The interventions under investigation include: Atazanavir/ Stavidine / Lamivudine (DRUG), Atazanavir-Ritonavir/ Stavidine / Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00084253?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00084253 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.